A peptide inhibitor derived from p55PIK phosphatidylinositol 3-kinase regulatory subunit: A novel cancer therapy

Molecular Cancer Therapeutics

Volumn 7, Issue 12, 2008, Pages 3719-3728

  Hu, Junbo ^a   Xia, Xianmin ^b,e   Cheng, Aiwu ^b   Wang, Guihua ^a   Luo, Xuelai ^a   Reed, Michael F ^c   Fojo, Tito ^d   Oetting, Alexis ^b   Gong, Jianping ^a   Yen, Paul M ^b,e  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; GREEN FLUORESCENT PROTEIN; P55PIK ENZYME; PEPTIDE N24; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; RETINOBLASTOMA PROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER THERAPY; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; THYROID CANCER; XENOGRAFT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; PEPTIDE FRAGMENTS; PEPTIDES; RETINOBLASTOMA PROTEIN;

EID: 57749095656     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0499     Document Type: Article

References (29)

1. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
2. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 2004;3:1221-4.
3. Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu Rev Biochem 1998;67:481-507.
4. Vanhaesebroeck B, Waterfield MD. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 1999;253:239-54.
5. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003;4:257-62.
6. Xia X, Cheng A, Akinmade D, Hamburger AW. The N-terminal 24 amino acids of the p55g regulatory subunit of phosphoinositide 3-kinase binds Rb and induces cell cycle arrest. Mol Cell Biol 2003;23:1717-25.
7. Zhang L, Huang J, Yang N, Greshock J, et al. Integrative genomic analysis of phosphatidylinositol 3′-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer. Clin Cancer Res 2007;13:5314-21.
8. Goretzki PE, Frilling A, Simon D, Roeher HD. Growth regulation of normal thyroids and thyroid tumors in man. Recent Results Cancer Res 1990;118:48-63.
9. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 1998;95:2509-14.
10. Dolbeare F, Gratzner H, Pallavicini MG, Gray JW. Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine. Proc Natl Acad Sci U S A 1983;80:5573-7.
11. Cheng A, Wang S, Cai J, Rao MS, Mattson MP. Nitric oxide acts in a positive feedback loop with BDNF to regulate neural progenitor cell proliferation and differentiation in the mammalian brain. Dev Biol 2003;258:319-23.
12. Reed MF, Zagorski WA, Howington JA, Zilfou JT, Knudsen ES. Inhibition of retinoblastoma tumor suppressor activity by RNA interference in lung cancer lines. Ann Thorac Surg 2006;82:249-53.
13. von Kleist S, Chany E, Burtin P, King M, Fogh J. Immunohistology of the antigenic pattern of a continuous cell line from a human colon tumor. J Natl Cancer Inst 1975;55:555-60.
14. Morrow CJ, Gray A, Dive C. Comparison of phosphatidylinositol-3-kinase signalling within a panel of human colorectal cancer cell lines with mutant or wild-type PIK3CA. FEBS Lett 2005;579:5123-8.
15. Takizawa CG, Morgan DO. Control of mitosis by changes in the subcellular location of cyclin-B1-1 and Cdc25C. Curr Opin Cell Biol 2000;12:658-65.
16. Bengoechea-Alonso MT, Punga T, Ericsson J. Hyperphosphorylation regulates the activity of SREBP1 during mitosis. Proc Natl Acad Sci U S A 2005;102:11681-6.
17. Warbrick E. The puzzle of PCNA's many partners. BioEssays 2000;22:997-1006.
18. Klippel A, Escobedo MA, Wachowicz MS, et al. Activation of phosphatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation. Mol Cell Biol 1998;18:5699-711.
19. Alvarez B, Martinez AC, Burgering BM, Carrera AC. Forkhead transcription factors contribute to execution of the mitotic programme in mammals. Nature 2001;413:744-7.
20. Garcia Z, Kumar A, Marques M, Cortes I, Carrera AC. Phosphoinositide 3-kinase controls early and late events in mammalian cell division. EMBO J 2006;25:655-61. Epub 2006 Jan 26.
21. 2/M phase of the cell cycle. Curr Biol 2002;12:919-24.
22. Mittnacht S. The retinoblastoma protein - from bench to bedside. Eur J Cell Biol 2005;84:97-107.
23. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002;2:103-12.
24. Wymann MP, Marone R. Phosphoinositide 3-kinase in disease: timing, location, and scaffolding. Curr Opin Cell Biol 2005;17:141-9.
25. Lee YH, White MF. Insulin receptor substrate proteins and diabetes. Arch Pharm Res 2004;27:361-70.
26. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001;414:799-806.
27. Ward SG, Finan P. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr Opin Pharmacol 2003;3:426-34.
28. Fan QW, Weiss WA. Isoform specific inhibitors of PI3 kinase in glioma. Cell Cycle 2006;5:2301-5.
29. Clayman GL, Frank DK, Bruso PA, Goepfert H. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res 1999;5:1715-22.